Diazoxide, ¶ a nondiuretic benzothiadiazine, has been found to have definite hyperglycemic properties, and its use in various forms of hypoglycemia has been the subject of several reports.

Diazoxide concentrations in protein and buffer solutions were measured by extraction with ethyl acetate and spectrophotometric determination of absorbance at 280 mμ. 7 Recovery of drug from both ...

Learn everything you need to know about Diazoxide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions ...

The relentless hunger and associated behaviours significantly impact the quality of life for those with Prader-Willi syndrome ...

The Company has been granted Orphan Drug Designation for diazoxide choline in the EU for the treatment of PWS, which could provide Soleno with up to 10 years of market exclusivity in the EU ...

The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline ...

The Company has been granted Orphan Drug Designation for diazoxide choline in the EU for the treatment of PWS, which could provide Soleno with up to 10 years of market exclusivity in the EU ...

The FDA approved extended-release diazoxide choline (Vykat XR) to treat the intense persistent sensation of hunger in patients 4 years of age and older with Prader-Willi syndrome, maker Soleno ...

Please provide your email address to receive an email when new articles are posted on . Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi ...

18 November 2024 Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans. As this appraisal has ...